Snyder R D, Diehl M S
Abbott Laboratories, D-468, AP13A, 100 Abbott Park Road, Abbott Park, IL 60064, USA.
Mutagenesis. 2000 May;15(3):203-5. doi: 10.1093/mutage/15.3.203.
We have recently reported on the use of a cell-based bleomycin amplification assay for the detection of DNA intercalating agents. In order to further validate this assay, two series of proprietary compounds were evaluated for frameshift mutagenesis in the Ames bacterial reversion system and for bleomycin amplification in the Chinese hamster V79 micronucleus system. It is shown that 10 of 11 frameshift-positive compounds were bleomycin amplifiers. These studies indicate that positive frameshift mutagenicity findings are consistent with expectations from the results of the bleomycin amplification assay, providing additional validation of the amplification assay for the detection of DNA intercalating agents. The studies also demonstrate that intercalation is necessary but not sufficient for frameshift mutagenesis since bleomycin amplifiers lacking frameshift mutagenic activity were also identified.
我们最近报道了一种基于细胞的博来霉素扩增试验用于检测DNA嵌入剂。为了进一步验证该试验，在艾姆斯细菌回复突变系统中评估了两个系列的专利化合物的移码诱变作用，并在中国仓鼠V79微核系统中评估了其博来霉素扩增情况。结果表明，11种移码阳性化合物中有10种是博来霉素扩增剂。这些研究表明，阳性移码诱变结果与博来霉素扩增试验结果的预期一致，为检测DNA嵌入剂的扩增试验提供了额外的验证。研究还表明，嵌入对于移码诱变是必要的，但不是充分的，因为也鉴定出了缺乏移码诱变活性的博来霉素扩增剂。
